A detailed history of Asset Management One Co., Ltd. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Asset Management One Co., Ltd. holds 76,502 shares of BMRN stock, worth $5.1 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
76,502
Previous 77,766 1.63%
Holding current value
$5.1 Million
Previous $6.4 Million 16.01%
% of portfolio
0.02%
Previous 0.02%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

SELL
$69.02 - $93.84 $87,241 - $118,613
-1,264 Reduced 1.63%
76,502 $5.38 Million
Q2 2024

Jul 18, 2024

SELL
$74.43 - $92.22 $207,510 - $257,109
-2,788 Reduced 3.46%
77,766 $6.4 Million
Q1 2024

May 02, 2024

SELL
$83.81 - $99.0 $45,173 - $53,361
-539 Reduced 0.66%
80,554 $7.04 Million
Q4 2023

Jan 24, 2024

SELL
$76.22 - $98.51 $365,017 - $471,764
-4,789 Reduced 5.58%
81,093 $7.82 Million
Q3 2023

Oct 19, 2023

SELL
$85.07 - $94.48 $95,108 - $105,628
-1,118 Reduced 1.29%
85,882 $7.6 Million
Q2 2023

Jul 31, 2023

BUY
$86.68 - $100.3 $173,099 - $200,299
1,997 Added 2.35%
87,000 $7.54 Million
Q1 2023

Apr 25, 2023

SELL
$87.74 - $117.27 $364,822 - $487,608
-4,158 Reduced 4.66%
85,003 $8.27 Million
Q4 2022

Feb 06, 2023

SELL
$80.93 - $108.63 $485,175 - $651,236
-5,995 Reduced 6.3%
89,161 $9.23 Million
Q3 2022

Nov 04, 2022

BUY
$82.16 - $96.94 $672,233 - $793,163
8,182 Added 9.41%
95,156 $8.07 Million
Q2 2022

Jul 29, 2022

SELL
$71.48 - $86.85 $143,245 - $174,047
-2,004 Reduced 2.25%
86,974 $7.21 Million
Q1 2022

May 13, 2022

SELL
$74.28 - $92.69 $275,355 - $343,601
-3,707 Reduced 4.0%
88,978 $6.86 Million
Q4 2021

Feb 09, 2022

BUY
$71.72 - $91.47 $875,701 - $1.12 Million
12,210 Added 15.17%
92,685 $8.31 Million
Q3 2021

Nov 02, 2021

BUY
$74.77 - $85.47 $105,874 - $121,025
1,416 Added 1.79%
80,475 $6.22 Million
Q2 2021

Aug 03, 2021

SELL
$75.51 - $84.79 $409,490 - $459,816
-5,423 Reduced 6.42%
79,059 $6.6 Million
Q1 2021

May 14, 2021

SELL
$74.73 - $90.69 $166,722 - $202,329
-2,231 Reduced 2.57%
84,482 $6.38 Million
Q4 2020

Feb 12, 2021

SELL
$72.61 - $90.2 $579,790 - $720,247
-7,985 Reduced 8.43%
86,713 $7.48 Million
Q3 2020

Nov 13, 2020

BUY
$71.87 - $131.03 $284,389 - $518,485
3,957 Added 4.36%
94,698 $7.2 Million
Q2 2020

Aug 14, 2020

SELL
$79.55 - $124.22 $200,306 - $312,785
-2,518 Reduced 2.7%
90,741 $11.2 Million
Q1 2020

May 14, 2020

BUY
$71.37 - $96.85 $175,356 - $237,960
2,457 Added 2.71%
93,259 $7.88 Million
Q4 2019

Feb 14, 2020

SELL
$64.27 - $86.37 $277,003 - $372,254
-4,310 Reduced 4.53%
90,802 $7.68 Million
Q3 2019

Nov 14, 2019

BUY
$67.4 - $85.11 $73,533 - $92,855
1,091 Added 1.16%
95,112 $6.41 Million
Q2 2019

Aug 14, 2019

BUY
$80.35 - $93.9 $5,222 - $6,103
65 Added 0.07%
94,021 $8.05 Million
Q1 2019

May 15, 2019

SELL
$84.2 - $98.62 $17 Million - $19.9 Million
-201,430 Reduced 68.19%
93,956 $8.35 Million
Q4 2018

Feb 13, 2019

BUY
$80.14 - $106.07 $822,156 - $1.09 Million
10,259 Added 3.6%
295,386 $25.1 Million
Q3 2018

Nov 14, 2018

BUY
$93.92 - $105.72 $288,897 - $325,194
3,076 Added 1.09%
285,127 $27.7 Million
Q2 2018

Aug 14, 2018

BUY
$76.01 - $99.03 $897,526 - $1.17 Million
11,808 Added 4.37%
282,051 $26.5 Million
Q1 2018

May 14, 2018

BUY
$77.67 - $92.63 $715,806 - $853,678
9,216 Added 3.53%
270,243 $21.9 Million
Q4 2017

Feb 14, 2018

SELL
$80.76 - $95.13 $769,723 - $906,684
-9,531 Reduced 3.52%
261,027 $23.3 Million
Q3 2017

Nov 14, 2017

SELL
$80.6 - $94.95 $45,136 - $53,172
-560 Reduced 0.21%
270,558 $25.2 Million
Q2 2017

Aug 14, 2017

BUY
N/A
271,118
271,118 $24.6 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Asset Management One Co., Ltd. Portfolio

Follow Asset Management One Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Asset Management One Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Asset Management One Co., Ltd. with notifications on news.